Roche’s reports positive data for FDC of Perjeta and Herceptin in breast cancer
Roche announced the phase III FeDeriCa study met its primary endpoint. The study showed a new investigational fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) demonstrated non-inferior levels of Perjeta in the blood (pharmacokinetics) compared to standard IV infusion. September 13, 2019